Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial

Background: Although biliary tract cancer (BTC) has a very aggressive nature, some patients maintain a relatively good performance status after failure with first-line treatment of gemcitabine plus cisplatin (GC). Thus, tolerable, feasible, and useful second-line treatments are needed for these pati...

詳細記述

保存先:
書誌詳細
出版年:J Cancer
主要な著者: Kim, Seung Tae, Oh, Sung Yong, Lee, Jeeyun, Kang, Jung Hun, Lee, Hyun Woo, Lee, Myung Ah, Sohn, Byeong Seok, Hong, Ji Hyong, Park, Young Suk, Park, Joon Oh, Lim, Ho Yeong
フォーマット: Artigo
言語:Inglês
出版事項: Ivyspring International Publisher 2019
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6856733/
https://ncbi.nlm.nih.gov/pubmed/31772650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.37610
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料